Minims (Prednisolone Sodium Phosphate)

Prednisolone Sodium Phosphate is used to treat ocular inflammatory conditions by reducing swelling and immune‑mediated responses.

• Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery.
• Allergic conjunctivitis: alleviates itching, tearing and conjunctival hyperemia caused by allergens.
• Uveitis: controls intra‑ocular inflammation and prevents tissue damage in anterior or intermediate uveitis.
• Other inflammatory eye conditions: manages inflammation associated with keratitis, scleritis or ocular trauma.

• Prednisolone Sodium Phosphate penetrates ocular tissues and binds intracellular glucocorticoid receptors. The receptor complex translocates to the nucleus and suppresses phospholipase A2 activity, decreasing arachidonic acid production. It also down‑regulates transcription of pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6 and tumor‑necrosis factor‑α, thereby limiting leukocyte infiltration and edema in the eye.

Topical ocular corticosteroids may cause a range of local and systemic adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Burning or stinging sensation upon instillation.
• Transient blurred vision.
• Increased intra‑ocular pressure.
• Mild ocular irritation or redness.
• Temporary tearing.

Serious or Rare Side Effects

• Secondary ocular infection (bacterial, fungal or viral).
• Persistent elevation of intra‑ocular pressure leading to glaucoma.
• Cataract formation with prolonged use.
• Delayed wound healing after ocular surgery.
• Systemic adrenal suppression (rare with extensive use).

When prescribing Minims, clinicians should consider several safety measures to minimize risks and ensure optimal therapeutic outcomes.

• Assess intra‑ocular pressure: monitor IOP before treatment and periodically during therapy.
• Screen for ocular infections: avoid use in active bacterial, fungal or viral eye infections unless combined with appropriate antimicrobial therapy.
• Limit duration: use the lowest effective dose for the shortest period required to control inflammation.
• Caution in glaucoma patients: evaluate risk‑benefit as steroids can raise IOP.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Store at ambient temperature: keep the bottle below 25 °C, protect from light, and retain in the original container with the cap tightly closed.

Prednisolone Sodium Phosphate may interact with other medications, altering its safety or efficacy profile.

Major Interactions (Avoid)

• Systemic CYP3A4 inhibitors: may increase systemic exposure if significant ocular absorption occurs.
• Concurrent use of potent ocular NSAIDs: can increase risk of corneal melting.

Moderate Interactions (Monitor Closely)

• Other topical corticosteroids: additive IOP‑raising effect; monitor pressure.
• Anticholinergic eye drops: may reduce tear film stability, increasing irritation.
• Systemic immunosuppressants: may enhance overall immunosuppression; observe for infections.